Segall Bryant & Hamill LLC Increases Holdings in Qiagen N.V. (NYSE:QGEN)

Segall Bryant & Hamill LLC grew its stake in Qiagen N.V. (NYSE:QGEN - Free Report) by 15.8% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 175,656 shares of the company's stock after buying an additional 23,967 shares during the quarter. Segall Bryant & Hamill LLC owned approximately 0.08% of Qiagen worth $7,053,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of QGEN. Groupama Asset Managment boosted its stake in shares of Qiagen by 8,074.0% during the 4th quarter. Groupama Asset Managment now owns 31,817,740 shares of the company's stock valued at $1,416,844,000 after buying an additional 32,216,761 shares during the period. Massachusetts Financial Services Co. MA lifted its stake in shares of Qiagen by 9.5% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 25,319,332 shares of the company's stock worth $1,127,470,000 after buying an additional 2,202,040 shares during the last quarter. Wellington Management Group LLP lifted its stake in shares of Qiagen by 2.5% during the 4th quarter. Wellington Management Group LLP now owns 21,782,305 shares of the company's stock worth $970,534,000 after buying an additional 531,362 shares during the last quarter. Vanguard Group Inc. increased its position in Qiagen by 0.9% during the fourth quarter. Vanguard Group Inc. now owns 8,879,089 shares of the company's stock worth $397,937,000 after acquiring an additional 77,119 shares during the period. Finally, Norges Bank acquired a new position in shares of Qiagen during the 4th quarter valued at $181,529,000. Institutional investors and hedge funds own 70.00% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the company. Barclays started coverage on Qiagen in a research report on Tuesday, June 24th. They issued an "overweight" rating and a $55.00 target price for the company. Robert W. Baird increased their target price on shares of Qiagen from $42.00 to $43.00 and gave the company a "neutral" rating in a report on Monday, April 21st. Wall Street Zen upgraded shares of Qiagen from a "buy" rating to a "strong-buy" rating in a report on Thursday, May 15th. Bank of America raised their price target on Qiagen from $50.00 to $53.00 and gave the stock a "buy" rating in a research report on Thursday, June 26th. Finally, Redburn Atlantic lowered shares of Qiagen from a "buy" rating to a "neutral" rating in a report on Friday, April 4th. Seven investment analysts have rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, Qiagen presently has a consensus rating of "Hold" and an average price target of $49.40.

Qiagen Stock Down 0.1%

Shares of NYSE:QGEN opened at $48.27 on Friday. The company has a debt-to-equity ratio of 0.40, a quick ratio of 2.83 and a current ratio of 3.37. The company has a fifty day moving average of $45.82 and a 200-day moving average of $42.95. Qiagen N.V. has a 52-week low of $37.63 and a 52-week high of $49.30. The company has a market capitalization of $10.73 billion, a PE ratio of 121.03, a price-to-earnings-growth ratio of 2.46 and a beta of 0.68.

Qiagen (NYSE:QGEN - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported $0.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.50 by $0.05. The business had revenue of $483.46 million during the quarter, compared to analyst estimates of $465.66 million. Qiagen had a net margin of 4.68% and a return on equity of 14.61%. The company's revenue was up 5.2% on a year-over-year basis. During the same period in the prior year, the business posted $0.44 earnings per share. On average, equities analysts predict that Qiagen N.V. will post 2.26 EPS for the current fiscal year.

Qiagen Announces Dividend

The company also recently announced a dividend, which was paid on Thursday, July 10th. Shareholders of record on Thursday, July 3rd were issued a $0.25 dividend. The ex-dividend date of this dividend was Wednesday, July 2nd. This represents a yield of 0.52%. Qiagen's dividend payout ratio (DPR) is 62.50%.

Qiagen Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.